PTGS2 and neoplasm: This was the objective of a very recent study in which the contribution of the COX-2/PGE2 pathway in IH-induced enhanced tumor malignancy was assessed using celecoxib as a COX-2 specific inhibitor in a murine model of OSA bearing LLC1 tumors [144].